For example, around 50% of children and young adult patients treated with tisagenlecleucel for R/R B-cell ALL had ≥ Grade 3 CRS (33, 91), 24% of adult patients infused with brexucabtagene autoleucel had ≥ Grade 3 CRS (36), while lower incidence of ≥ Grade 3 CRS, 8.6% and 2.9% respectively, was observed after CD22-CART cell treatment (39, 41). This evidence concerns the gene CD22 and congenital rubella syndrome.